Pfizer (NY:<a title="Quote for Pfizer" href="https://markets.financialcontent.com/ricentral/quote?Symbol=NY%3APFE">PFE )

These income stocks look like smart buys right now.

The Smartest Dividend Stocks to Buy With $3,000 Right Now ↗

December 28, 2025

The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Pfizer Confirms Death Of Patient Enrolled In Hemophilia Drug Study ↗

December 23, 2025

Via Stocktwits

3 Drug Stocks to Buy at a Discount ↗

December 27, 2025

3 Superb High-Yield Dividend Stocks With Yields North of 5% That Make for No-Brainer Buys Right Now ↗

Topics Intellectual Property

December 27, 2025

High dividend yields don't matter if they aren't supported by quality businesses.

Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Friday and uncover the stocks that are leading the way in terms of trading volume and market...

Looking for the most active stocks in the S&P500 index on Friday? ↗

December 26, 2025

Via Chartmill

Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology

December 26, 2025

As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine...

NEW YORK — On December 16, 2025, Pfizer (NYSE:PFE) issued a conservative financial outlook for the 2026 fiscal year, falling short of Wall Street’s expectations and signaling a prolonged period of...

Topics Economy Intellectual Property

Pfizer’s 2026 Outlook Misses the Mark as Post-Pandemic Hangover and Patent Cliff Loom

December 25, 2025

The Great Vaccine Consolidation: Sanofi’s $2.2 Billion Strategic Bet on Dynavax Technologies

Topics Economy Intellectual Property

December 25, 2025

Dateline: December 25, 2025 Introduction In a move that has sent shockwaves through the biotechnology and pharmaceutical sectors on this Christmas Day, the global vaccine landscape has been...

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

Topics Economy Intellectual Property

As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?

December 25, 2025

Via Barchart.com

Topics Workforce

Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever ↗

December 24, 2025

If you are looking for high yields, this drug maker and this device maker are both worth a deep dive today.

The Atomic Architect: How University of Washington’s Generative AI Just Rewrote the Rules of Medicine

Topics Intellectual Property

December 24, 2025

In a milestone that many scientists once considered a "pipe dream" for the next decade, researchers at the University of Washington’s (UW) Institute for Protein Design (IPD) announced in late 2025 the...

Via TokenRing AI

Topics Artificial Intelligence

Stay informed about the most active stocks in the S&P500 index on Wednesday's session. ↗

December 24, 2025

Explore the S&P500 index on Wednesday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.

Via Chartmill

Moderna (MRNA) Deep-Dive: Navigating the 7.5% Year-End Slide and the Path to a 2028 Recovery

December 24, 2025

As of December 24, 2025, Moderna, Inc. (Nasdaq: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the definitive success story of the pandemic era, the Cambridge-based...

Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine

Topics Initial Public Offering

December 24, 2025

As of today, December 24, 2025, the global pharmaceutical landscape is witnessing a profound consolidation of power within specialty medicine and immunology. Sanofi (NASDAQ: SNY; Euronext: SAN), the...

Pfizer stands as one of the world’s largest pharmaceutical companies, with a broad portfolio spanning vaccines, oncology, and immunology.

Topics Artificial Intelligence Economy Intellectual Property

“Setting Up The Second Act” Stock Market (And Sentiment Results)… ↗

December 24, 2025

Via Talk Markets

Is Fidelity Medical Equipment the Ultimate "Forever Fund" for Health Care Investors? ↗

December 24, 2025

This basket of 64 medical device stocks could raise its dividend for decades.

Shares of Novo Nordisk (NYSE: NVO) surged more than 8% in early trading on December 23, 2025, after the pharmaceutical giant secured a landmark FDA approval for its high-dose oral semaglutide, branded...

Topics ETFs Government Supply Chain

Novo Nordisk Stock Soars as "Wegovy Pill" Gains FDA Approval, Reshaping Obesity Market

December 23, 2025

The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave

December 23, 2025

As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results...

Novo Nordisk Breaks the Mold: Oral Obesity Breakthrough Sends Shares to New Heights as Pharma Landscape Shifts

Topics Intellectual Property

December 23, 2025

BAGSVAERD, Denmark — In a landmark decision that has sent shockwaves through the global pharmaceutical industry, Novo Nordisk (NYSE:NVO) has secured U.S. Food and Drug Administration (FDA) approval for...

Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. ↗

Topics Economy

December 23, 2025

Stay informed about the most active stocks in the S&P500 index on Tuesday's session. Discover the stocks that are generating the highest trading volume and driving market activity.

Via Chartmill

Pfizer Reports Patient Death In Marstacimab Hemophilia Extension Study ↗

December 23, 2025

Pfizer disclosed a patient death in a marstacimab hemophilia study, triggering a safety review and reassessment of surgical protocols.

Via Benzinga

The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025

December 23, 2025

After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The...

As the curtain closes on 2025, the global financial landscape is witnessing a seismic shift in corporate strategy. After two years of "wait-and-see" posturing dictated by high interest rates and...

Topics Economy

The Great Consolidation: Why 2026 is Set to Become the 'Year of the Mega-Deal'

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Topics Artificial Intelligence Economy Government

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As of December 22, 2025, the global equity markets are witnessing a historic recalibration of the healthcare sector. For decades, the "Trillion Dollar Club" was an exclusive enclave for Silicon...

Topics ETFs Economy Intellectual Property

The Incretin Empire: Eli Lilly’s (LLY) Path to a $1 Trillion Market Cap and Beyond

December 22, 2025

As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare...

Topics Economy Intellectual Property

The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth

December 22, 2025

As of December 22, 2025, Moderna, Inc. (NASDAQ: MRNA) stands at a critical juncture in its corporate evolution. Once the poster child for the biotechnology industry’s rapid response to the global...

Topics Economy Intellectual Property

Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive

December 22, 2025

Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead? ↗

Topics Earnings Initial Public Offering Intellectual Property

December 22, 2025

Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader.